INSPECT-IPD Aims to Flag Problematic Randomized Controlled Trials Before Bad Data Spread
The integrity of a randomized trial can fail long before a paper is retracted. When individual participant data are available, those failures may become visible in ways that aggregate tables can hide: impossible patterns, inconsistent treatment allocation, unusual outcome clustering, or data structures that do not fit the biology of the condition being studied.
This medRxiv protocol describes the development of INSPECT-IPD, a tool intended to identify problematic randomized controlled trials using participant-level data. The project is not a treatment study and not a conventional clinical trial in the therapeutic sense; it is a quality-assurance effort aimed at research reliability. In an era when meta-analyses can influence practice, guidelines, and reimbursement decisions, the ability to detect compromised trials upstream has direct consequences for patient care.
The rationale is straightforward. If a trial contains fabrication, severe reporting error, duplicated participants, or other structural irregularities, downstream synthesis can absorb those flaws and distort the evidence base. Participant-level data give investigators a finer lens than published summary statistics, making it possible to inspect balance, timing, distributional features, and internal consistency across randomized groups. In practice, this kind of scrutiny may matter as much as the intervention itself, because one flawed study can bend the apparent effect of an entire body of evidence.
Participant-Level Scrutiny as a Defense Against Faulty Evidence
The protocol brings together a wide multidisciplinary group, spanning biostatistics, obstetrics and gynecology, maternal-fetal medicine, surgery, psychology, epidemiology, evidence synthesis, and replication research. That breadth fits the task. Detecting a suspect randomized controlled trial is not only a statistical exercise; it also requires clinical judgment about whether the observed data patterns make biological or procedural sense.
A participant-level approach can expose problems that remain invisible when only published means and confidence intervals are available. For example, unusually tidy baseline balance, implausible heaping of values, repeated sequences, or outcome distributions that look detached from real-world variability can all raise concern. Likewise, inconsistencies between randomization claims and observed data structures can signal deeper methodological failure. The protocol positions INSPECT-IPD as a way to organize such checks into a reproducible framework rather than relying on ad hoc suspicion.
This matters because randomization is not merely a design label; it is the mechanism that protects against confounding. When randomization is broken, the trial no longer performs the function readers assume it does. A corrupted trial may still look polished in print, yet its conclusions can become unstable or actively misleading when placed inside a systematic review.
Why This Tool Matters for Evidence Synthesis and Clinical Decision-Making
The clinical stakes extend beyond academic housekeeping. Systematic reviews and guideline panels often treat randomized trials as the highest tier of evidence, but that hierarchy assumes the trials are genuinely randomized and internally credible. If a compromised trial contributes to a pooled estimate, clinicians may receive an effect size that is more precise than it deserves to be and more persuasive than it should be.
Participant data offer the chance to inspect the structure of the trial at a level summary reports cannot match. That opens the door to detecting anomalies in recruitment patterns, baseline comparability, outcome timing, and treatment assignment that would otherwise remain buried. For specialties where trial evidence is sparse or highly influential, a single unreliable study can have outsized impact. Obstetrics, maternal-fetal medicine, vascular surgery, and other fields represented by the author group are all areas where practice decisions may hinge on relatively small evidence bases.
A tool such as INSPECT-IPD could therefore serve as a filter before a study enters secondary analysis, not after damage is done. It may also help standardize how concerns are raised, documented, and evaluated. In evidence synthesis, consistency is a form of protection. A common framework can reduce the subjectivity that often surrounds judgments about trial credibility.
What the Protocol Signals About Research Quality Control
The project reflects a wider shift in clinical science toward data auditing and reproducibility. As more investigators request or obtain individual participant data for review, the pressure grows for methods that can identify irregularities without depending entirely on narrative impressions. The protocol’s emphasis on a tool rather than a single case review suggests an effort to make credibility assessment scalable.
The scope is important. This is not about proving misconduct in a courtroom sense. It is about separating robust randomized evidence from data that should not be treated as equally trustworthy. That distinction influences how meta-analysts weight studies, how guideline authors interpret signals, and how clinicians understand uncertainty in the literature.
A strong screening method would not eliminate the need for expert review. It would create a structured first pass, identifying trials that deserve closer inspection before they are folded into pooled analyses or practice recommendations. In a system where false certainty can be as harmful as true error, that kind of guardrail has real clinical value.
The Remaining Challenge Is Validation, Not Just Design
The protocol itself cannot show whether INSPECT-IPD will successfully identify the kinds of trials it is meant to catch. That question will depend on how the tool performs once it is applied to real datasets with known or suspected problems, and whether it preserves specificity while still flagging meaningful anomalies. A screening approach that is too sensitive could burden reviewers with false alarms; one that is too lax could miss exactly the studies it was built to detect.
Even so, the premise is consequential. When participant-level data are available, trial credibility should no longer rest only on surface impressions from published reports. A method that interrogates the data structure itself could become an important part of modern evidence appraisal, especially in fields where the clinical cost of trusting a flawed randomized controlled trial is high.